Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis cuts sales forecast, diabetes drug approval delayed
Novartis has been hit by competing generic versions of its heart drug Lotrel and anti-nail fungus treatment Lamisil, and the withdrawl of its bowel disorder drug Zelnorm after
Novartis has been hit by competing generic versions of its heart drug Lotrel and anti-nail fungus treatment Lamisil, and the withdrawl of its bowel disorder drug Zelnorm after
The company’s findings also show that all doses of HE3286 (10mg to 100mg) appear to be safe and well tolerated in healthy volunteers with no reported drug related
Existing investors Sofinnova Partners and Index Ventures both significantly increased their equal investment in Swiss-based GlycoVaxyn, after having seeded the company in July 2006. GlycoVaxyn will use the
The publication reported that those behind the pioneering facility are claiming that it will revolutionize the way that chemicals used in commonplace products are manufactured. The bdaily website
According to Arpida, the results of the second trial, called ASSIST-2, (Arpida’s Skin and Skin Structure Infection STudies), validated the results of the first phase of testing, ASSIST-1.
In a press release regarding the decision to suspend the development of valopicitabine, Idenix said that it was disappointed with the FDA’s decision, and that the company would
The company said that the drug, currently named V3381, was generally well-tolerated and that the data showed that further clinical development was warranted. V3381 is a novel drug
The legal case was brought against Orphan Medical Inc, a subsidiary of Jazz Pharmaceuticals. Orphan Medical pled guilty to one count of felony misbranding of a pharmaceutical product.
prGCD is a proprietary plant cell expressed recombinant form of human Glucocerebrosidase (GCD), for the treatment of Gaucher disease, a lysosomal storage disorder in humans. The phase III
The trial, an open-label Phase III study of Erbitux plus a taxane and carboplatin in the first-line treatment for metastatic non-small cell lung cancer (NSCLC), did not meet